UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/532,373	04/21/2005	Desmond John Best	P33128USw	3876	
23347 GLAXOSMIT	7590 01/16/2008 HKI INF	EXAMINER			
CORPORATE INTELLECTUAL PROPERTY, MAI B475 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398			DAVIS, ZINNA NORTHINGTON		
			ART UNIT	PAPER NUMBER	
	,		1625		
•		NOTIFICATION DATE	DELIVERY MODE		
-			01/16/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USCIPRTP@GSK.COM ROSALIE.M.CHAMBERLAIN@GSK.COM JULIE.D.MCFALLS@GSK.COM

		Application	No	Applicant(s)			
		10/532,373		BEST ET AL.			
	Office Action Summary	Examiner		Art Unit			
•		Zinna Northir	noton Davis	1625			
	The MAILING DATE of this communication app						
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ 2a)⊟	Responsive to communication(s) filed on <u>31 C</u> This action is FINAL . 2b) This	is action is no					
3)□	, _			raccoution as to the morite is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-3,5, 7,12,14-17,21 and 23</u> is/are pending in the application.							
4a) Of the above claim(s) <u>21</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1,2,16,17 and 23</u> is/are rejected.							
7)🖂	Claim(s) $3.5,7,12,14$ and 15 is/are objected to.			•			
	Claim(s) are subject to restriction and/or	r election req	uirement.				
	on Papers						
· · · · · ·	The specification is objected to by the Examine						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.							
· · · · · · · · · · · · · · · · · · ·							
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1.☐ Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage.							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>se</u>	4) 5) ee cont . 6)	Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)			

10/532,373

3) April 21, 2005 and September 4, 2007

Application/Control Number: 10/532,373

Page 2

Art Unit: 1625

DETAILED ACTION

- 1. Claims 1-3, 5, 7, 12, 14-17, 21 and 23 are pending. Claims 4, 8-11, 13, 18-20, and 22 have been canceled.
- 2. Based upon the response filed October 31, 2007, Applicants have elected Group I, claims 1-3, 5-7, 12, 14-17, and 23, without traverse. The preferred species of claim

16 is represented as follows:

- 3. Claim 21 is withdrawn from consideration.
- 4. Based upon the examination and search, the species election is withdrawn. The claims are examined as a whole.
- 5. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).
- 6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Art Unit: 1625

7. Claim 23 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 23 improperly refers to claim 1. It is suggested that the compound of formula I should be depicted or the claim should depend upon claim 1.

Clarification is appreciated.

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 9. Claims 1, 2, 16, and 17 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Jonas et al (Reference B, cited by the Examiner).

The instantly claimed compound is disclosed. At page 13, lines 62 and 63, and page 15, lines 56-57, see the named compound, 5-[1-[3- methoxy-4-3- dimethylamino)propoxy]-benzoyl)-1,2,3,4-tetrahydroquinoline-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one.

The claims are fully met when a =1; b=2; q=3; R^1 is heterocycle; R^2 is hydrogen; R^4 is $-(CH_2)_q$ -N $R^{11}R^{12}$; and R^{11} and R^{12} are alkyl.

The compound is depicted below:

Application/Control Number: 10/532,373

Art Unit: 1625

10. Claim 1, 2, 16, 17, and 23 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by NOVO NORDISK A/S (Reference 10, cited by Applicants).

The instantly claimed compound is disclosed. At page 15, lines 22-23, see the named compound, [7-Chloro-1-(2,3-dihydrobenzofuran-7-yl)-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]- [4-(2-dimethylaminoethoxy)-phenyl]-methanone, (compound No. 39). At page 22, lines 15-28, see the reaction process.

Compound No. 39 is depicted bellow:

The claims are fully met when a and b=2; q=2; R^1 is CI and -OMe; R^2 is heterocycle; R^4 is $-(CH_2)_q$ -N $R^{11}R^{12}$; and R^{11} and R^{12} are alkyl.

11. Claims 3, 5, 7, 12, 14, and 15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Application/Control Number: 10/532,373

Art Unit: 1625

12. Reference A is cited to show the state of the art.

13. The Information Disclosure Statements filed April 21, 2005 and September 4,

2007 have been considered.

14. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Zinna Northington Davis whose telephone number is

571-272-0682.

15. The fax phone number for the organization where this application or proceeding

is assigned is 571-273-8300 for regular communications.

16. Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Zinna Northington Davis/
Zinna Northington Davis

Page 5

Primary Examiner

Art Unit 1625

Znd 12.31, 2007